Keywords: scios, sees, positive, natrecor, data, last, nda

Scios sees positive Natrecor data at last, NDA amendment to be filed by

Article | 16 November 2000

Print This

Scios Inc has revealed positive data from a Phase III trial of its leadproduct Natrecor (nesiritide), a b-type natriuretic peptide, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in